Preliminary results from a phase I expansion study of ZG005, a bispecific antibody targeting TIGIT and PD-1, as monotherapy in patients with advanced solid tumors

被引：0
|
作者：
Qin, Shukui
Cheng, Ying
Wang, Qiming
Cheng, Shuxia
Chai, Xiaoli
Wu, Lihua
Yu, Yan
Shi, Jianhua
Li, Xiumin
Fan, Lianlian
Xia, Jin
Huang, Yisheng
Ji, Yinghua
Zhuang, Zhixiang
Yang, Lei
Jiang, Ou
Zheng, Qinhong
Liao, Sihai
Yi, Shanyong
Ye, Huangyang
机构：
[1] Nanjing Chinese Med Univ, Jinling Hosp, Canc Ctr, Nanjing, Peoples R China
[2] Jilin Canc Hosp, Changchun, Peoples R China
[3] Zhengzhou Univ, Affiliated Canc Hosp, Zhengzhou, Peoples R China
[4] Henan Canc Hosp, Zhengzhou, Peoples R China
[5] ChangSha TaiHe Hosp, Changsha, Peoples R China
[6] Shulan (Hangzhou) Hosp, Hangzhou, Peoples R China
[7] Harbin Med Univ, Internal Med Dept 6, Canc Hosp, Harbin, Peoples R China
[8] Linyi Canc Hosp, Linyi, Shandong, Peoples R China
[9] Linyi Canc Hosp, Dept Gynecol Oncol, Linyi, Shandong, Peoples R China
[10] Deyang Peoples Hosp, Deyang, Peoples R China
[11] Anyang Tumor Hosp, Anyang, Henan, Peoples R China
[12] Maoming Peoples Hosp, Dept Oncol, Maoming, Peoples R China
[13] Xinxiang Med Univ, Affiliated Hosp 1, Xinxiang, Henan, Peoples R China
[14] Soochow Univ, Dept Oncol, Affiliated Hosp 2, Suzhou, Peoples R China
[15] Nantong Canc Hosp, Nantong, Peoples R China
[16] Second Peoples Hosp Neijiang, Neijiang, Peoples R China
[17] Peoples Hosp Quzhou, Quzhou, Peoples R China
[18] Guangdong Med Univ, Affiliated Hosp, Zhanjiang, Peoples R China
[19] Zhengzhou Cent Hosp, Dept Med Oncol, Zhengzhou, Peoples R China
[20] Xiamen Univ, Affiliated Hosp 1, Xiamen, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2611
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors
    Muik, Alexander
    Garralda, Elena
    Altintas, Isil
    Gieseke, Friederike
    Geva, Ravit
    Ben-Ami, Eytan
    Maurice-Dror, Corinne
    Calvo, Emiliano
    LoRusso, Patricia M.
    Alonso, Guzman
    Rodriguez-Ruiz, Maria E.
    Schoedel, Kristina B.
    Blum, Jordan M.
    Sanger, Bianca
    Salcedo, Theodora W.
    Burm, Saskia M.
    Stanganello, Eliana
    Verzijl, Dennis
    Vascotto, Fulvia
    Sette, Angelica
    Quinkhardt, Juliane
    Plantinga, Theo S.
    Toker, Aras
    van den Brink, Edward N.
    Fereshteh, Mark
    Diken, Mustafa
    Satijn, David
    Kreiter, Sebastian
    Breij, Esther C. W.
    Bajaj, Gaurav
    Lagkadinou, Eleni
    Sasser, Kate
    Tureci, Ozlem
    Forssmann, Ulf
    Ahmadi, Tahamtan
    Sahin, Ugur
    Jure-Kunkel, Maria
    Melero, Ignacio
    CANCER DISCOVERY, 2022, 12 (05) : 1248 - 1265
  • [22] Phase I study of IBI322 (anti-CD47/PD-L1 bispecific antibody) monotherapy therapy in patients with advanced solid tumors in China.
    Wang, Jie
    Sun, Yuping
    Chu, Qian
    Duan, Jianchun
    Wan, Rui
    Wang, Zhijie
    Zhao, Jun
    Li, Haoyuan
    Guo, Yingmei
    Chen, Yuling
    Wang, Yan
    CANCER RESEARCH, 2022, 82 (12)
  • [23] Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors
    Ma, Yuxiang
    Xue, Jinhui
    Zhao, Yuanyuan
    Zhang, Yang
    Huang, Yan
    Yang, Yunpeng
    Fang, Wenfeng
    Guo, Ye
    Li, Qun
    Ge, Xiaoxiao
    Sun, Jie
    Zhang, Bangyong
    Zhang, Yuhan
    Xiao, Jinyuan
    Zhang, Li
    Zhao, Hongyun
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (06)
  • [24] PHASE I STUDY OF ONO-4538 (BMS-936558), AN ANTI PD-1 ANTIBODY, IN JAPANESE PATIENTS WITH ADVANCED SOLID TUMORS
    Yamamoto, N.
    Yamada, Y.
    Nokihara, H.
    Asahina, H.
    Shibata, T.
    Tamura, Y.
    Seki, Y.
    Honda, K.
    Tanabe, Y.
    Tamura, T.
    ANNALS OF ONCOLOGY, 2012, 23 : 159 - 159
  • [25] Preliminary Phase 1 Results of the PD-1 Inhibitor ABBV-181 in Japanese vs Western Patients With Advanced Solid Tumors
    Kuboki, Yasutoshi
    Kondo, Shunsuke
    Drew, Rasco
    John, Powderly
    Alexander, Spira
    Jason, J. Luke
    Daniel, Afar
    Stefan, Englert
    Hashiba, Hideyuki
    Stacie, Lambert
    Apurvasena, Parikh
    Shimizu, Eisuke
    Greg, Vosganian
    Doi, Toshihiko
    Yamamoto, Noboru
    ANNALS OF ONCOLOGY, 2019, 30
  • [26] Intravenous (IV) infusion of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody, as monotherapy in advanced solid tumors: Preliminary results from an ongoing phase 1/2a study
    Niu, Jiaxin
    Barve, Minal A.
    Spira, Alexander I.
    Edenfield, William Jeffery
    Pang, Weijia
    Fu, Wenmin
    Lu, Yingxin
    McKean, Meredith
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [27] The first-in-class bispecific antibody IBI318 (LY3434172) targeting PD-1 and PD-L1 in patients with advanced tumors: a phase Ia/Ib study
    Ruan, Dan-Yun
    Wei, Xiao-Li
    Liu, Fu-Rong
    Hu, Xi-Chun
    Zhang, Jian
    Ji, Dong-Mei
    Huang, Ding-Zhi
    Zhao, Yan-Qiu
    Pan, Hong-Min
    Liao, Wang-Jun
    Yang, Kun-Yu
    Xu, Nong
    Lu, Xiao-Xiao
    Chen, Yu-Ling
    Zhang, Wen
    Zhou, Hui
    Zhao, Hong-Yun
    Xu, Rui-Hua
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2024, 17 (01)
  • [28] A Phase 1 study of INCMGA00012, a PD-1 inhibitor, in patients with advanced solid tumors: Preliminary results for patients with advanced cervical cancer (POD1UM-101)
    Mehnert, Janice
    Paz Ares, Luis
    Pikiel, Joanna
    Banerji, Udai
    Kryzhanivska, Anna
    Lakhani, Nehal
    Ochsenreiter, Sebastian
    Arkenau, Tobias
    Bourayou, Nawel
    Kornacki, Deanna
    Tian, Chuan
    Condamine, Thomas
    Gardeazabal Gonzalez, Itziar
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [29] EARLY RESULTS FROM A PHASE 1 STUDY TO EVALUATE SAFETY, PHARMACOKINETICS, AND EFFICACY OF AMG 404, A PROGRAMMED DEATH-1 (PD-1) ANTIBODY, IN PATIENTS WITH ADVANCED SOLID TUMORS
    Price, Timothy
    Chawla, Sant
    Falchook, Gerald
    Prenen, Hans
    Lugowska, Iwona
    Subbiah, Vivek
    Monzon, Jose
    Ozawa, Yuichi
    Arkenau, Tobias
    Lima, Caio Rocha
    Kuboki, Yasutoshi
    Nishina, Tomohiro
    Hui, Mun
    Rasmussen, Erik
    Wong, Hansen
    Najmi, Saltanat
    Sadraei, Nooshin
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A245 - A245
  • [30] PRELIMINARY SAFETY, PHARMACOKINETICS/PHARMACODYNAMICS, AND ANTITUMOR ACTIVITY OF XMAB20717, A PD-1 X CTLA-4 BISPECIFIC ANTIBODY, IN PATIENTS WITH ADVANCED SOLID TUMORS
    Shum, Elaine
    Daud, Adil
    Reilley, Matthew
    Najjar, Yana
    Thompson, John
    Baranda, Joaquina
    Harvey, R. Donald
    Leidner, Rom
    Shields, Anthony
    Cohen, Ezra
    Cohen, Roger
    Mita, Alain
    Pant, Shubham
    Stein, Mark
    Chmielowski, Bartosz
    Hu-Lieskovan, Siwen
    Fleener, Catherine
    Ding, Ying
    Chollate, Sowmya
    Avina, Hector
    Shorr, Jolene
    Clynes, Raphael
    Hickingbottom, Barbara
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A247 - A248
12345